BioSpace News Archive

The global biomarkers market size is expected to reach USD 130.65 Billion in 2028 at a CAGR of 13.6% during the forecast period, according to latest report by Reports and Data.

The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products. Top companies in the market are focusing on R&D activities to expand their product offerings and cater to unmet medical needs of the global population.

NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the devastating effects of traumatic brain injury (TBI), today provided an update on the development of its lead drug candidates NTS-104 and NTS-105 in traumatic brain injury.

Invacare Corporation announced that Matt Monaghan, chairman, president and chief executive officer, will present at the 12th Annual East Coast IDEAS Investor Conference on Wednesday, June 22, 2022.

Clinical laboratory tests refer to various medical tests performed in a laboratory to gain information about the health condition of a patient by using their blood or urine samples.

According to the latest report by Reports and Data, the global dental imaging market size was USD 2.54 Billion in 2020 and is expected to reach USD 4.88 Billion in 2028 and register a revenue CAGR of 8.4% during the forecast period, 2021-2028.

The latest market analysis report published by Reports and Data, titled ‘Global Dry Eye Drugs Market – Forecast to 2028,’ thoroughly examines the Dry Eye Drugs industry to provide essential data & information for the targeted readers. The report consists of quantitative and qualitative research on the market performed by our market experts.

PineTree Therapeutics, Inc., an emerging leader in pioneering the development of disruptive therapies in Oncology, Immuno-oncology and other diseases, announced that the company has raised $23.5 Million for Series A1 funding.

Prapela, Inc. has submitted its unique bassinet pad for FDA clearance as a complementary treatment for newborns suffering from opioid withdrawal.

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurological disorders and conditions, including Alzheimer’s disease (AD), is pleased to acknowledge Alzheimer’s & Brain Awareness Month in June as an opportunity to raise awareness about brain disorders including AD and other dementias as a major public health issue.